-

05:47:18 AM

ETON Stock News

ETON - Eton Pharmaceuticals Inc

06/24/22 9:09 AM

NYSE, Nasdaq : RDY, ETON

acquisition

Dr. Reddy';s Laboratories Announces the Acquisition of an Injectable Product Portfolio from Eton Pharma

Reddy’ s Laboratories Ltd. today announced that it has acquired a portfolio of branded and generic injectable products from Deer Park, Illinois based- Eton Pharmaceuticals, Inc.. The portfolio includes the Biorphen ® Injection and Rezipres ® Injection NDAs with nine separate combinations of strengths and presentations and one first-to-file approved...

RHEA-AI

neutral

06/24/22 7:30 AM

Nasdaq : ETON

low float

Eton Pharmaceuticals Announces Sale of Hospital Products

Eton sold its rights in Biorphen®, Rezipres®, and Cysteine Hydrochloride products for total payments of up to $50 million Going forward, Eton’s commercial portfolio will exclusively focus on products that treat rare diseases Eton’s royalty portfolio is now eligible to receive up to $70 million in

RHEA-AI

very positive

05/12/22 4:02 PM

Nasdaq : ETON

earningslow float

Eton Pharmaceuticals Reports First Quarter 2022 Financial Results

Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the first quarter ended March 31, 2022. “We are proud to

RHEA-AI

very positive

05/03/22 4:02 PM

Nasdaq : ETON

conferencesearningslow float

Eton Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2022 financial results on Thursday, May 12,

RHEA-AI

neutral

04/11/22 4:01 PM

Nasdaq : ETON

managementlow float

Eton Pharmaceuticals Appoints James Gruber as Chief Financial Officer

Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of James Gruber as Chief Financial Officer, effective

RHEA-AI

positive

04/11/22 7:30 AM

Nasdaq : ETON

fda approvallow float

Eton Pharmaceuticals Announces FDA Approval of Cysteine Hydrochloride Injection

Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has received final approval from the U.S. Food and Drug Administration

RHEA-AI

positive

03/16/22 4:02 PM

Nasdaq : ETON

earningslow float

Eton Pharmaceuticals Reports Fourth Quarter 2021 Financial Results

Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for

RHEA-AI

neutral

03/14/22 7:00 AM

Nasdaq : ETON

low float

Eton Pharmaceuticals and XGen Pharmaceuticals DJB Announce Commercial Launch of Rezipres® (ephedrine hydrochloride), a Ready-to-Use Formulation of Injectable Ephedrine (4.7 mg/mL)

Eton Pharmaceuticals, Inc. (Nasdaq: ETON) and XGen Pharmaceuticals DJB, Inc. today announced the commercial availability of Rezipres® (ephedrine hydrochloride) injection. Rezipres (4.7 mg/mL) is a ready-to-use 1 formulation of injectable

RHEA-AI

very positive

03/08/22 8:00 AM

Nasdaq : ETON

conferencesearningslow float

Eton Pharmaceuticals to Report Fourth Quarter 2021 Financial Results on Wednesday, March 16, 2022

Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter 2021 financial results on Wednesday, March

RHEA-AI

neutral

12/20/21 7:30 AM

Nasdaq : ETON

low float

Eton Pharmaceuticals and ANI Pharmaceuticals Announce Commercial Availability of Carglumic Acid Tablets, the First and Only FDA-Approved Generic Version of Carbaglu® (carglumic acid)

RHEA-AI

positive